share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  04/19 16:21

Moomoo AI 已提取核心訊息

On April 17, 2024, 180 Life Sciences Corp. announced significant changes to its financial oversight and legal proceedings. The company, with the approval of its Audit Committee, has dismissed Marcum LLP as its independent registered public accounting firm and has engaged M&K CPAs, PLLC for the fiscal year ending December 31, 2024. The previous audit reports by Marcum for the years ending December 31, 2023, and 2022 did not contain any adverse opinions, except for an uncertainty regarding the company's ability to continue as a going concern. In legal matters, 180 Life Sciences reported progress in its ongoing litigation with AmTrust International Underwriters DAC and Freedom Specialty Insurance Company. The court granted partial summary judgment in favor of 180 Life Sciences, affirming the company's insured status and...Show More
On April 17, 2024, 180 Life Sciences Corp. announced significant changes to its financial oversight and legal proceedings. The company, with the approval of its Audit Committee, has dismissed Marcum LLP as its independent registered public accounting firm and has engaged M&K CPAs, PLLC for the fiscal year ending December 31, 2024. The previous audit reports by Marcum for the years ending December 31, 2023, and 2022 did not contain any adverse opinions, except for an uncertainty regarding the company's ability to continue as a going concern. In legal matters, 180 Life Sciences reported progress in its ongoing litigation with AmTrust International Underwriters DAC and Freedom Specialty Insurance Company. The court granted partial summary judgment in favor of 180 Life Sciences, affirming the company's insured status and coverage for certain SEC subpoena-related expenses. However, issues regarding the Change in Control exclusion remain unresolved and will be determined at trial. The company has already received $2.27 million from AmTrust, of which $1.5 million was retained after attorney's fees. The final matters of the litigation are to be vigorously pursued by 180 Life Sciences.
2024年4月17日,180生命科學公司宣佈對其財務監督和法律程序進行重大調整。經審計委員會批准,該公司已解除Marcum LLP作爲其獨立註冊會計師事務所的資格,並已在截至2024年12月31日的財政年度聘請了M&K CPA, PLLC。Marcum先前對截至2023年12月31日和2022年12月31日的年度的審計報告不包含任何負面意見,但公司繼續作爲持續經營企業的能力存在不確定性外。在法律事務方面,180 Life Sciences報告了與AmTrust國際承保人DAC和自由專業保險公司正在進行的訴訟的進展。法院作出了有利於180 Life Sciences的部分即決判決,確認了該公司的...展開全部
2024年4月17日,180生命科學公司宣佈對其財務監督和法律程序進行重大調整。經審計委員會批准,該公司已解除Marcum LLP作爲其獨立註冊會計師事務所的資格,並已在截至2024年12月31日的財政年度聘請了M&K CPA, PLLC。Marcum先前對截至2023年12月31日和2022年12月31日的年度的審計報告不包含任何負面意見,但公司繼續作爲持續經營企業的能力存在不確定性外。在法律事務方面,180 Life Sciences報告了與AmTrust國際承保人DAC和自由專業保險公司正在進行的訴訟的進展。法院作出了有利於180 Life Sciences的部分即決判決,確認了該公司的保險狀況以及某些與美國證券交易委員會傳票相關的費用的承保範圍。但是,有關控制權變更排除的問題仍未解決,將在審判中確定。該公司已經從AmTrust獲得了227萬美元,其中150萬美元是在扣除律師費後留存的。180 Life Sciences 將積極處理訴訟的最後事項。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息